Clinical trial Recruiting at 1 site Observational Ages 60 to 80 Women only

Cartilage biomarker response to acute loading in knee OA by antiresorptive treatment status

Official title: Response of Cartilage Degradation Biomarkers to Acute Mechanical Loading and the Effect of Antiresorptive Therapy in Postmenopausal Women With Mild-to-Moderate Knee Osteoarthritis

Run by Sisli Hamidiye Etfal Training and Research Hospital · NCT07881861 · Data updated 2026-11-12

Researchers will test whether a 30-minute treadmill walk changes cartilage biomarkers in postmenopausal women with knee osteoarthritis, comparing those on denosumab, bisphosphonates, and those not on antiresorptives.

More Knee Osteoarthritis trials

Quick facts

Study typeObservational
Ages60 Years to 80 Years
SexWomen only
Enrollment105 (estimated)
SponsorSisli Hamidiye Etfal Training and Research Hospital
Academic / other
Drugs / interventionsprednisone, denosumab
Locations1 site (Istanbul, Istanbul)
StatusRecruiting
StartedMay 8, 2026
Main results expectedFebruary 10, 2027
Study endsFebruary 10, 2027
Registry record updatedOctober 20, 2026
Trial IDNCT07881861 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Postmenopausal women aged 60–80 with DEXA-confirmed osteoporosis or osteopenia and radiographically confirmed knee OA (Kellgren-Lawrence grade 2 or 3).

Probably not a fit

Patients not responsive to mechanical loading in terms of biomarker changes or those outside the antiresorptive groups may see no demonstrated benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study groups postmenopausal women with mild-to-moderate knee OA by antiresorptive treatment status and subjects them to a standardized 30-minute treadmill walk. Blood samples taken just before and within 2 minutes after walking will be analyzed for cartilage degradation biomarkers such as COMP and MMP-3. The goal is to see if the biomarker response to acute mechanical loading differs based on antiresorptive therapy. Eligible participants are between 60 and 80 years old, with osteoporosis or osteopenia, and imaging-confirmed knee OA (K/L grades 2–3). No interventional treatment is being tested; the study observes natural biomarker changes in relation to existing medications.

Why it matters

Potential benefit: If successful, findings could help tailor exercise recommendations and clarify how antiresorptive therapies influence cartilage health responses to loading.

How similar studies have gone: Prior work has explored how mechanical loading and biomarkers relate to cartilage health, but this study's stratification by antiresorptive status is a relatively novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Postmenopausal women aged 60-80 years.
* DEXA-confirmed diagnosis of osteoporosis or osteopenia.
* Clinically and radiographically confirmed knee osteoarthritis, with Kellgren-Lawrence grade 2 or 3 in at least one knee.
* Knee MRI performed within the previous 3 months.
* Bilateral hand radiographs performed within the previous 6 months.
* Pain intensity of at least 20 mm on the Visual Analog Scale (VAS) during activity.
* Ability to tolerate the standardized acute mechanical loading protocol consisting of 30 minutes of treadmill walking.
* Non-sarcopenic status according to the STAR protocol.
* Ability to provide written informed consent.

Exclusion Criteria:

* Inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
* Active gout or calcium pyrophosphate deposition (CPPD) attack.
* History of total knee arthroplasty or major knee surgery.
* Intra-articular knee injection within the previous 12 months.
* Change in antiresorptive therapy within the previous 6 months.
* Previous osteoanabolic therapy.
* Systemic corticosteroid use for ≥3 months at a dose equivalent to ≥5 mg/day of prednisone.
* Glomerular filtration rate (eGFR) \<30 mL/min.
* New York Heart Association (NYHA) class III-IV heart failure.
* Uncontrolled diabetes mellitus or hypertension.
* Neurological disease significantly limiting walking.
* Cognitive impairment.

Where it's running

  • Sisli Hamidiye Etfal Training and Research Hospital
    Istanbul, Istanbul, Turkey (Türkiye)
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.